Search for a trial

Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria

To relate the reduction of inflammatory characteristics in skin and in peripheral blood to clinical efficacy in patients with CSU. Major focusses of this study are the (early) effects on basophils and other Fc*RI-bearing leukocytes before, during,…

Prevalence of latex allergy among operating room employees in the Netherlands

Research questions:What is the current prevalence of latex allergy among operating room employees from Erasmus Medical Centre, Rotterdam? Is the sensitisation prevalence significantly lower compared to the prevalence before introducing non powdered…

Efficacy and safety of canakinumab in Schnitzler syndrome

Primary: To determine whether IL-1 inhibition by Canakinumab is efficacious in treatment of Schnitzler syndrome.Secondary:1. To assess the effect of canakinumab on Schnitzler syndrome (clinical signs/symptoms and inflammatory biomarkers C-reactive…

An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in preceding studies with LOU064

To assess the long-term safety and tolerability of LOU064 in patients with CSU who have participated in preceding studies with LOU064.

Conestat alfa as prophylactic treatment for idiopathic non-histaminergic acquired angioedema

The primary objective of this exploratory study is to test if prophylactic use of conestat alfa decreases the frequency of angioedema attacks in patients with InH-AAE. As secondary objectives, effects on disease severity, quality of life and drug…

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of
Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic
Angioedema with Normal C1-Inhibitor (C1-INH)

Primary: To evaluate the long-term safety of repeated subcutaneous(SC) administrations of lanadelumab in adolescents and adults with nonhistaminergicangioedema with normal C1-INH

A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301

The purpose of the study is to establish the efficacy and safety of ligelizumab in treating adult and adolescent subjects with chronic spontaneous urticaria. This study also looks how:• further treatment of ligelizumab works following ligelizumab or…

An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema

This study has been transitioned to CTIS with ID 2024-517249-15-00 check the CTIS register for the current data. Primary Objective:To evaluate the safety of extended dosing, and alternative dosing and/or dose frequency with ISIS 721744 in patients…

An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

This study has been transitioned to CTIS with ID 2023-509201-77-00 check the CTIS register for the current data. Primary ObjectiveTo evaluate the safety of long-term dosing with donidalorsen in patients with HAE. Secondary ObjectivesTo evaluate the…

A virtual, decentralised observational follow-up study investigating feeding patterns in infancy and the associated parent-reported allergic manifestations, allergies and infections in childhood.

Given the worldwide-observed rapid increase in the prevalence of allergic diseases, it is likely that environmental risk factors, including geographic area and lifestyle factors play a substantial role in the development of allergies and other…